Business Description
Galectin Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3632252025
Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.36 | |||||
| Equity-to-Asset | -2.14 | |||||
| Debt-to-Equity | -1.19 | |||||
| Debt-to-EBITDA | -1.88 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15.9 | |||||
| 3-Year EPS without NRI Growth Rate | -21.4 | |||||
| 3-Year FCF Growth Rate | -14.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.86 | |||||
| 9-Day RSI | 52.83 | |||||
| 14-Day RSI | 58.96 | |||||
| 6-1 Month Momentum % | 0.48 | |||||
| 12-1 Month Momentum % | 2.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.77 | |||||
| Quick Ratio | 1.77 | |||||
| Cash Ratio | 1.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -13.76 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -183.41 | |||||
| ROIC % | -2620.96 | |||||
| ROC (Joel Greenblatt) % | -5221.56 | |||||
| ROCE % | -373.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -6.71 | |||||
| EV-to-EBITDA | -6.72 | |||||
| EV-to-FCF | -7.8 | |||||
| Earnings Yield (Greenblatt) % | -14.9 | |||||
| FCF Yield % | -15.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GALT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galectin Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.74 | ||
| Beta | 0.85 | ||
| Volatility % | 44.56 | ||
| 14-Day RSI | 58.96 | ||
| 14-Day ATR ($) | 0.293102 | ||
| 20-Day SMA ($) | 3.179 | ||
| 12-1 Month Momentum % | 2.94 | ||
| 52-Week Range ($) | 1.28 - 4.2684 | ||
| Shares Outstanding (Mil) | 61.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galectin Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galectin Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galectin Therapeutics Inc Frequently Asked Questions
What is Galectin Therapeutics Inc(GALT)'s stock price today?
The current price of GALT is $3.37. The 52 week high of GALT is $4.27 and 52 week low is $1.28.
When is next earnings date of Galectin Therapeutics Inc(GALT)?
The next earnings date of Galectin Therapeutics Inc(GALT) is 2024-05-15 Est..
Does Galectin Therapeutics Inc(GALT) pay dividends? If so, how much?
Galectin Therapeutics Inc(GALT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers